Zacks Investment Research
12 Oct 2026, 22:51 UTC · 1h ago
Here's Why Moderna (MRNA) Fell More Than Broader Market
Impact · against what's priced in
The article provides no new catalysts for Moderna, as the projected earnings declines and revenue volatility are already reflected in the current valuation. The stock's recent price action reflects a premium for the oncology pipeline that transcends these short-term respiratory franchise headwinds.
- MRNA+0.00
Already priced in
- The price assumes
The current respiratory vaccine franchise, which generated $1.94 billion in FY2025 revenue despite a 39.2% year-over-year decline.
The projected quarterly revenue decline of 12.52% and the projected EPS drop of 168.63% simply confirm the ongoing volatility and decline of the respiratory franchise that the market has already accounted for.
What MRNA's price assumes · Sep 11
Search tags
